Abstract
Background A 17-year-old Filipino male hemodialysis patient presented for renal transplant evaluation. He had significant skeletal abnormalities characterized by bone pain, an inability to walk, and secondary hyperparathyroidism despite therapy with an active vitamin D sterol (paricalcitol).
Investigations The patient underwent a physical examination, and his serum levels of calcium, phosphorus, alkaline phosphatase, parathyroid hormone, aluminum and 25-hydroxycholecalciferol (25OH-vitamin D) were determined. X-rays of hips and lower extremities, MRI, and bone histomorphometry after double tetracycline labeling were performed.
Diagnosis Osteomalacia associated with low 25OH-vitamin D levels.
Management Monthly therapy with ergocalciferol (vitamin D2) and discontinuation of paricalcitol.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
National Kidney Foundation Kidney Disease Outcomes Quality Initiative (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42 (Suppl 3): S1–S201
Chapuy MC et al. (1992) Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 327: 1637–1642
Eastwood JB et al. (1977) The effect of 25-hydroxy vitamin D3 in the osteomalacia of chronic renal failure. Clin Sci Mol Med 52: 499–508
Ghazali A et al. (1995) Is low plasma 25-(OH) vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Kidney Int 55: 2169–2177
Thomas MK et al. (1998) Hypovitaminosis D in medical inpatients. N Engl J Med 338: 777–783
Gordon CM et al. (2004) Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med 158: 531–537
van der Wielen RP et al. (1995) Serum vitamin D concentrations among elderly people in Europe. Lancet 346: 207–210
González EA et al. (2004) Vitamin D insufficiency and deficiency in chronic kidney disease: a single center observational study. Am J Nephrol 24: 503–510
LaClair RE et al. (2005) Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 45: 1026–1033
Levin A et al. (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71: 31–38
Langman C (1987) Childhood uremic bone disease. Pediatr Ann 16: 974–978
Mehls O (1984) Renal osteodystrophy in children: etiology and clinical aspects. In End Stage Renal Disease in Children, 227–250 (Eds Fine RN and Gruskin AB) Philadelphia: WB Saunders
Holick MF (2002) Vitamin D: the underappreciated D-lightful hormone that is important for skeletal and cellular health. Curr Opin Endocrinol Diabetes 9: 87–98
Mawer EB and Davies M (2001) Vitamin D nutrition and bone disease in adults. Rev Endocr Metab Disord 2: 153–164
Dusso AS et al. (1991) Extrarenal production of calcitriol in normal and uremic humans. J Clin Endocrinol Metab 72: 157–164
Fournier A et al. (1979) Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization. Kidney Int 15: 196–204
Cunningham J and Makin H (1997) How important is vitamin D deficiency in uraemia? Nephrol Dial Transplant 12: 16–18
Coen G et al. (2005) 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy. Kidney Int 68: 1840–1848
Fournier A et al. (1998) Renal osteodystrophy in dialysis patients: diagnosis and treatment. Artif Organs 22: 530–557
Goodman WG et al. (1994) Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46: 1160–1166
Acknowledgements
This work was supported in part by NIH Research Project Grants DK675632, DK35423 and RR-00865, and funds from the Casey Lee Ball Foundation. The authors would like to thank William G Goodman for his histomorphometric analyses and interpretations of the patient's bone biopsies.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
IB Salusky has received honorarium from Abbott Laboratories (speakers' bureau) and Genzyme. The other authors declared they have no competing interests.
Rights and permissions
About this article
Cite this article
Hernandez, J., Wesseling, K., Boechat, M. et al. Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol. Nat Rev Nephrol 3, 227–232 (2007). https://doi.org/10.1038/ncpneph0443
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpneph0443
This article is cited by
-
Case report: Osteomalacia due to bisphosphonate treatment in a patient on hemodialysis
BMC Nephrology (2021)
-
Osteoporosis, bone mineral density and CKD–MBD: treatment considerations
Journal of Nephrology (2017)
-
Osteomalacia induced by vitamin D deficiency in hemodialysis patients: the crucial role of vitamin D correction
Journal of Bone and Mineral Metabolism (2014)
-
Vitamin D deficiency and toxicity in chronic kidney disease: in search of the therapeutic window
Pediatric Nephrology (2010)
-
Vitamin D receptor activation and survival in chronic kidney disease
Kidney International (2008)